Neuronetics Inc. (NASDAQ: STIM) stock gained by 2.91% at last close while the STIM stock price surges by 5.65% in the after-hours trading session. Neuronetics, Inc. is an advertising medical technology business that focuses on creating, manufacturing, and selling solutions that help people with mental illnesses live better lives.
>> 7 Top Picks for the Post-Pandemic Economy <<
STIM stock’ Recent Development
Neuronetics has launched a new website to address customer demand for information on innovative depression therapies. Healthcare practitioners will be able to learn more about this essential therapy option for their patients’ thanks to the improved site. The leading non-drug and non-invasive transcranial magnetic stimulation (TMS) solution for depression is NeuroStar Advanced Therapy for Mental Health.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
According to the latest market research study commissioned by Neuronetics, 67 percent of patients with Major Depressive Disorder (MDD) are not satisfied with their current treatment, 60 percent wish there were better options, and 56 percent are very interested in learning about new depression treatment options, highlighting the critical need for more mental health resources and awareness on a national level. In response to the findings, the Company has redesigned its website to provide new material in a consolidated center that reflects what patients need to make educated decisions regarding depression treatment.
Keith J. Sullivan, President, and CEO of Neuronetics commented,
They are a firm dedicated to helping people get better and changing their lives. It is more critical than ever to empower patients and clinicians with the skills they need to combat depression as they confront a mental health crisis on the wake of the COVID-19 epidemic. Especially because they know that many patients are dissatisfied with their existing therapies and are interested in novel treatments like NeuroStar. One of the many ways they are making it simpler for people to deal with depression is by improving the user experience and updating their website to emphasize trustworthy, need-to-know information about NeuroStar as a therapy option.